Trial Profile

ALICIA (Observational Prospective Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Russia)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms ALICIA
Sponsors AstraZeneca

Most Recent Events

28 Jun 2024 Status changed from recruiting to active, no longer recruiting.
26 Oct 2022 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
26 Oct 2022 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com